These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 191532)

  • 1. Stimulation of mouse migration inhibitory factor (MIF) production form MSV-immune lymphocytes by soluble tumor-associated antigen: requirement for histocompatible macrophages.
    Landolfo S; Herberman RB; Holden HT
    J Immunol; 1977 Apr; 118(4):1244-8. PubMed ID: 191532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage-lymphocyte interaction in migration inhibition factor (MIF) production against soluble or cellular tumor-associated antigens. I. Characteristics and genetic control of two different mechanisms of stimulating MIF production.
    Landolfo S; Herberman RB; Holden HT
    J Immunol; 1978 Aug; 121(2):695-701. PubMed ID: 79613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
    Plata F; Jongeneel V; Cerottini JC; Brunner KT
    Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble factors in tolerance and contact sensitivity to 2,4-dinitrofluorobenzene in mice. IV. Characterization of migration inhibition factor-producing lymphocytes and genetic requirements for activation.
    Moorhead JW; Murphy JW; Harvey RP; Hayes RL; Fetterhoff TJ
    Eur J Immunol; 1982 May; 12(5):431-6. PubMed ID: 7047175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional activation of immune lymphocytes by antigenic stimulation in cell-mediated immunity. IV. Role of macrophage and its soluble factor in antigen-induced MIF production of immune T lymphocytes.
    Yamamoto Y; Onoue K
    J Immunol; 1979 Mar; 122(3):942-8. PubMed ID: 376710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune interferon. II. Different cellular site for the production of murine macrophage migration inhibitory factor and interferon.
    Neumann C; Sorg C
    Eur J Immunol; 1978 Aug; 8(8):582-9. PubMed ID: 359337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro studies of cell-mediated immunity to Moloney murine leukemia virus and Moloney leukemia-associated surface antigens.
    Ng AK; Ames RS; McIntire RK; Herberman RB
    Cancer Res; 1979 Dec; 39(12):4887-93. PubMed ID: 387218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation between cytotoxic lymphocytes and cells that synthesize the macrophage migration inhibitory factor in the H-2 system].
    Suslov AP; Egorova SG; Brondz BD
    Biull Eksp Biol Med; 1975 Oct; 80(10):86-90. PubMed ID: 776251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractoriness to migration inhibitory factor of macrophages of LPS nonresponder mouse strains.
    Tagliabue A; McCoy JL; Herberman RB
    J Immunol; 1978 Oct; 121(4):1223-6. PubMed ID: 359704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular immunity to murine sarcoma virus-induced tumors as measured by macrophage migration inhibition assays.
    Landolfo S; Herberman RB; Holden HT
    J Natl Cancer Inst; 1977 Dec; 59(6):1675-83. PubMed ID: 200758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor inhibiting capacity of spleen and lymph node cells from mice with murine sarcoma virus (MSV-M)-induced tumors.
    Weiland E; Mussgay M
    Z Immunitatsforsch Exp Klin Immunol; 1975 Nov; 150(5):414-23. PubMed ID: 181922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Participation of spleen cells in regulating the production of macrophage migration inhibitory factor in mice].
    Koval'chuk LV; Sotnikova NIu
    Biull Eksp Biol Med; 1981 Mar; 91(3):336-8. PubMed ID: 7018617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of a serine-protease with macrophage migration-inhibitory factor activity by virus-transformed cells and human tumor cell lines.
    Poste G
    Cancer Res; 1975 Sep; 35(9):2558-66. PubMed ID: 167963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.
    Basombrío MA; Mayer AM; Pasqualini CD
    Cancer Res; 1977 Jun; 37(6):1768-76. PubMed ID: 192461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histamine-induced suppressor factor (HSF): effect on migration inhibitory factor (MIF) production and proliferation.
    Rocklin RE
    J Immunol; 1977 May; 118(5):1734-8. PubMed ID: 67146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressor T cells regulate the cytolytic T lymphocyte response to syngeneic tumors induced by murine sarcoma virus (MSV) in the mouse.
    Plata F; MacDonald HR; Shain B
    J Immunol; 1979 Aug; 123(2):852-60. PubMed ID: 156765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization to effector lymphocytes associated with immunity to murine sarcoma virus (MSV)-induced tumors. II. Repeated stimulation and proliferation in vitro of specific cytolytic T lymphocytes.
    Plata F; Jongeneel CV
    J Immunol; 1977 Aug; 119(2):623-9. PubMed ID: 196025
    [No Abstract]   [Full Text] [Related]  

  • 18. [Development of the cellular immunity reaction to tuberculin in mice of different genotypes].
    Koval'chuk LV; Sokolova EV; Burtseva LV
    Biull Eksp Biol Med; 1976 Aug; 82(8):972-4. PubMed ID: 799940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV) induced tumors. I. Physical properties of cytolytic T lymphocytes generated in vitro and of their immediate progenitors.
    Plata R; MacDonald HR; Engers HD
    J Immunol; 1976 Jul; 117(1):52-8. PubMed ID: 180182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
    Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
    J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.